Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00514696
• Date of registration: 08/08/2007
• Primary sponsor: Prospect Therapeutics, Inc.
• Public title: Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia PR-CS008
• Scientific title: Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
• Date of first enrolment: February 2007
• Target sample size: 12
• Recruitment status: Suspended
• URL: http://clinicaltrials.gov/show/NCT00514696
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: David Smith, MD
• Affiliation: US Oncology

Key inclusion & exclusion criteria

Inclusion Criteria:

Eligible subjects must meet all of the following criteria:

1. Subject is capable of understanding the purpose and risks of the study and is able to
provide written Informed Consent.

2. Subject is male or female, aged at least 18 years.

3. Subject has been diagnosed with chronic lymphocytic leukemia.

4. Subject has Stage II or higher, chronic lymphocytic leukemia that currently requires
therapy due to the severity of the disease symptoms and/or to the presence of
increasing anemia and/or increasing splenomegaly.

5. Subject has received 2 or fewer prior therapies for his/her chronic lymphocytic
leukemia.

6. Subject does not currently require blood transfusions.

7. Subject's peripheral blood leukocyte count is > 10,000 cells/mm3.

8. Subject's Karnofsky performance status is > 60%.

9. Subject's life expectancy is at least 3 months.

10. Female subjects of childbearing potential (i.e., women who have not been surgically
sterilized or have not been post-menopausal for at least 1 year), and male subjects
with partners of childbearing potential, must agree to use medically acceptable
methods of contraception throughout the entire study period.

11. Subject is willing and able to comply with the prescribed treatment protocol and
evaluations.

Exclusion Criteria:

Subjects will be ineligible for study participation if they meet any of the following
criteria:

1. Subject received biologic therapy and/or chemotherapy that may be active against
chronic lymphocytic leukemia within the 4 weeks prior to Study Day 1.

2. Subject is anticipated to require steroid therapy within the next 21 days.

3. Subject received an investigational (i.e., experimental) therapy within the 4 weeks
prior to Study Day 1.

4. Subject's clinical laboratory values meet any of the following criteria within the 7
days prior to Study Day 1:

- Platelet count < 25,000 cells/mm3

- Absolute neutrophil count < 500 cells/mm3

- Hemoglobin < 8.0 g/dL and with an autoimmune hemolytic component to the
subject's anemia

- AST and/or ALT > 2.5 X the upper limit of normal

- Total bilirubin > 1.5 X the upper limit of normal

- Serum creatinine > 2 mg/dL

5. Subject has a known history of human immunodeficiency virus (HIV), hepatitis B,
and/or hepatitis C infection.

6. Subject has a clinically relevant active infection and/or a serious co-morbid medical
condition, such as recent myocardial infarction, unstable angina,
difficult-to-control congestive heart failure, uncontrolled hypertension,
difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive
pulmonary disease, cirrhosis, inflammatory bowel disease.

7. Subject had major surgery within the 4 weeks prior to Study Day 1.

8. Subject had another malignancy within the 3 years prior to study entry, with the
exception of adequately treated basal cell or squamous cell skin cancer, in situ
cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for
which the subject has been disease-free for at least 3 years.

9. If female, subject is pregnant or breast-feeding.

10. Subject has a concomitant disease or condition, including laboratory abnormalities,
which in the opinion of the Investigator could interfere with the conduct of the
study or could put the subject at unacceptable risk.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Chronic Lymphocytic Leukemia

Intervention(s)

Drug: GCS-100

Primary Outcome(s)

To Evaluate the effect of GCS-100 on markers of apoptosis in subjects with chronic lymphocytic leukemia using physical examinations, vital signs, lab assessments, and adverse event reporting [Time Frame: Up to 15 cycles X 21 days]

Secondary Outcome(s)

To evaluate the effect of GCS-100 on peripheral blood leukocyte count in subjects with chronic lymphocytic leukemia using complete blood count, leukocyte count and circulating cells for apoptosis [Time Frame: Hour 6 after Day 1 dosing, and Days 4 and 8]

Secondary ID(s)

PR-CS008

Source(s) of Monetary Support

Please refer to primary and secondary sponsors